Livzon Pharma Maintains 887.91 million Authorised Shares; Public Float Meets HKEX Requirement in April 2026

Bulletin Express05-06

Livzon Pharmaceutical Group Inc. submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 6 May 2026, covering movements in securities for the month ended 30 April 2026.

Authorised / Registered Share Capital • Ordinary H shares: 299.81 million shares at RMB 1 par value; no change during the month. • Ordinary A shares: 588.10 million shares at RMB 1 par value; no change during the month. • Total authorised share capital remained at 887.91 million shares, equivalent to RMB 887.91 million.

Issued and Treasury Shares • Issued H shares stood unchanged at 299.81 million, with zero treasury shares. • Issued A shares remained at 588.10 million, with zero treasury shares. • No share issuances, cancellations, repurchases, or treasury share movements were recorded.

Capital-Raising Instruments No share options, warrants, convertible securities, or other agreements to issue shares were outstanding or exercised during the period.

Public Float Compliance Livzon Pharma confirmed compliance with the Main Board Rule 13.32D(1) regarding the minimum 5 percent public float requirement for its H shares as at 30 April 2026.

Governance Confirmation The filing was signed by Secretary Liu Ning, affirming that all necessary authorisations, regulatory filings, and listing rule requirements related to the issuer’s securities have been satisfied.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105615223?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105615223","market":"us","top_or_hot":-1,"title":"Livzon Pharma Maintains 887.91 million Authorised Shares; Public Float Meets HKEX Requirement in April 2026","media":"Bulletin Express","content":"<p>Livzon Pharmaceutical Group Inc. submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 6 May 2026, covering movements in securities for the month ended 30 April 2026.</p>\n<p>Authorised / Registered Share Capital  \n• Ordinary H shares: 299.81 million shares at RMB 1 par value; no change during the month.  \n• Ordinary A shares: 588.10 million shares at RMB 1 par value; no change during the month.  \n• Total authorised share capital remained at 887.91 million shares, equivalent to RMB 887.91 million.</p>\n<p>Issued and Treasury Shares  \n• Issued H shares stood unchanged at 299.81 million, with zero treasury shares.  \n• Issued A shares remained at 588.10 million, with zero treasury shares.  \n• No share issuances, cancellations, repurchases, or treasury share movements were recorded.</p>\n<p>Capital-Raising Instruments  \nNo share options, warrants, convertible securities, or other agreements to issue shares were outstanding or exercised during the period.</p>\n<p>Public Float Compliance  \nLivzon Pharma confirmed compliance with the Main Board Rule 13.32D(1) regarding the minimum 5 percent public float requirement for its H shares as at 30 April 2026.</p>\n<p>Governance Confirmation  \nThe filing was signed by Secretary Liu Ning, affirming that all necessary authorisations, regulatory filings, and listing rule requirements related to the issuer’s securities have been satisfied.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Livzon Pharma Maintains 887.91 million Authorised Shares; Public Float Meets HKEX Requirement in April 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLivzon Pharma Maintains 887.91 million Authorised Shares; Public Float Meets HKEX Requirement in April 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-06 17:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Livzon Pharmaceutical Group Inc. submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 6 May 2026, covering movements in securities for the month ended 30 April 2026.</p>\n<p>Authorised / Registered Share Capital  \n• Ordinary H shares: 299.81 million shares at RMB 1 par value; no change during the month.  \n• Ordinary A shares: 588.10 million shares at RMB 1 par value; no change during the month.  \n• Total authorised share capital remained at 887.91 million shares, equivalent to RMB 887.91 million.</p>\n<p>Issued and Treasury Shares  \n• Issued H shares stood unchanged at 299.81 million, with zero treasury shares.  \n• Issued A shares remained at 588.10 million, with zero treasury shares.  \n• No share issuances, cancellations, repurchases, or treasury share movements were recorded.</p>\n<p>Capital-Raising Instruments  \nNo share options, warrants, convertible securities, or other agreements to issue shares were outstanding or exercised during the period.</p>\n<p>Public Float Compliance  \nLivzon Pharma confirmed compliance with the Main Board Rule 13.32D(1) regarding the minimum 5 percent public float requirement for its H shares as at 30 April 2026.</p>\n<p>Governance Confirmation  \nThe filing was signed by Secretary Liu Ning, affirming that all necessary authorisations, regulatory filings, and listing rule requirements related to the issuer’s securities have been satisfied.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01513","symbol_name":"丽珠医药","start_time":0,"source_url":"","article_id":"1105615223","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105615223","pubTimestamp":1778058194,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Livzon Pharmaceutical Group Inc. submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 6 May 2026, covering movements in securities for the month ended 30...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01513":"丽珠医药"},"translate_title":"丽珠医药持有88791万股法定股份；公众持股量于2026年4月达到港交所要求","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01513":1},"content_text":"Livzon Pharmaceutical Group Inc. submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 6 May 2026, covering movements in securities for the month ended 30 April 2026.\nAuthorised / Registered Share Capital  \n• Ordinary H shares: 299.81 million shares at RMB 1 par value; no change during the month.  \n• Ordinary A shares: 588.10 million shares at RMB 1 par value; no change during the month.  \n• Total authorised share capital remained at 887.91 million shares, equivalent to RMB 887.91 million.\nIssued and Treasury Shares  \n• Issued H shares stood unchanged at 299.81 million, with zero treasury shares.  \n• Issued A shares remained at 588.10 million, with zero treasury shares.  \n• No share issuances, cancellations, repurchases, or treasury share movements were recorded.\nCapital-Raising Instruments  \nNo share options, warrants, convertible securities, or other agreements to issue shares were outstanding or exercised during the period.\nPublic Float Compliance  \nLivzon Pharma confirmed compliance with the Main Board Rule 13.32D(1) regarding the minimum 5 percent public float requirement for its H shares as at 30 April 2026.\nGovernance Confirmation  \nThe filing was signed by Secretary Liu Ning, affirming that all necessary authorisations, regulatory filings, and listing rule requirements related to the issuer’s securities have been satisfied.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105615223","isCrawlerRequest":true}